(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Showing 1 - 7 of 7 records.
This phase I trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia. ...More
This phase II trial is studying the side effects of and how well Alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. ...More
Primary Determine the response rate in pediatric patients with recurrent or resistant malignant germ cell tumors treated with paclitaxel, ifosfamide, and carboplatin. SecondaryDetermine the toxicity of this regimen in these patients. Projected Accrual A total of 20 patients will be accrued for this...More
This Phase II trial will study how well sorafenib tosylate works in treating younger patients with relapsed or refractory Rhabdomyosarcoma, Wilms Tumors, Liver cancer or Thyroid cancer ...More
This phase I trial studies the side effects and best dose of tivantinib in treating younger patients with relapsed or refractory solid tumors. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth....More
This phase I trial studies the side effects and the best dose of crizotinib giving together with combination chemotherapy in treating younger patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. Crizotinib may stop the growth of tumor or cancer cells by blocking some...More
This phase I/II trial studies the side effects
and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in
treating younger patients with solid tumors that have come back or that have
not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan
hydrochloride may stop the...More
Cincinnati Children’s is involved in research because it is very important to understanding diseases and developing ways to prevent and treat health problems in children, as well as adults. Learn more about how you can help. Contact us at firstname.lastname@example.org or 513-636-0098. Or, enroll in our database to be notified about future studies by completing an online sign up form.
The Office for Clinical and Translational Research at Cincinnati Children’s provides sponsors and investigators with comprehensive support services, research tools, personnel and facilities to conduct or facilitate pediatric and adult clinical research studies. Contact us at OCTR@cchmc.org or 513-636-0314.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2016 Cincinnati Children's Hospital Medical Center